144 - May 30, 2025 | SEC Filings

Brief

Rocket Lab officer Arjun Kampani filed Form 144 on 2025-05-30 to sell 28,988 common shares (21,371 + 7,617) valued at ~$773k on NASDAQ via Morgan Stanley. Shares stem from restricted stock units vesting on 2025-05-22 as compensation. This routine insider transaction certifies no undisclosed material adverse information.

Detailed Brief

Form 144 discloses proposed sales by Rocket Lab Corp officer Arjun Kampani of 21,371 shares (market value $569,752) and 7,617 shares ($203,069), totaling 28,988 shares on 2025-05-30. These originate from 52,473 restricted stock units vesting on 2025-05-22 (38,685 + 13,788 shares acquired as compensation). Sales cover tax obligations from vesting, a standard practice. In the past three months, Kampani sold 39,390 shares: 5,277 on 2025-05-28 ($151,767), 5,277 on 2025-03-17 ($102,124), and 28,836 on 2025-03-14 ($524,276). Kampani represents no knowledge of undisclosed material adverse information about Rocket Lab. This fits Rocket Lab's pattern of executive equity awards in the space launch sector, where stock-based compensation aligns incentives amid growth investments.

Key Telemetry

• Arjun Kampani (officer) to sell 28,988 common shares (~$773k value) on 2025-05-30 to cover taxes on 52,473 RSUs vested 2025-05-22.

• Past 3 months: Sold 39,390 shares totaling ~$778k (May 28: 5,277; Mar 17: 5,277; Mar 14: 28,836).

• Routine Rule 144 filing; certifies no undisclosed adverse info.

• Shares outstanding: 461,432,393; negligible dilution (~0.006%).

Impact Vector

Routine sell-to-cover for taxes signals no bearish insider view, as required certification confirms no hidden issues. Minimal impact on stock price given small volume vs. float. Investors should monitor aggregate insider selling trends and Rocket Lab's Q2 results for execution on launches like Neutron.